

(19) AUSTRALIAN PATENT OFFICE

(54) Title
Method of detecting mutations in the gene encoding Cytochrome P450-2C19

(51)⁶ International Patent Classification(s)
C12Q 1/68 (2006.01) 20060101AFI2006042
C12Q 1/68 7BHAU
PCT/CA2005/001180

(21) Application No: 2005266805 (22) Application Date: 2005 .07 .29

(87) WIPO No: W006/010266

(30) Priority Data

(31) Number	(32) Date	(33) Country
60/592,124	2004 .07 .30	US

(43) Publication Date : 2006 .02 .02

(71) Applicant(s)
Luminex Molecular Diagnostics, Inc.

(72) Inventor(s)
Gordon, James D., Merante, Frank

(74) Agent/Attorney
Shelston IP, Level 21 60 Margaret Street, Sydney, NSW, 2000

(56) Related Art
WO 00/47766 A1, 17 August 2000
WO 02/059355 A2, 1 August 2002

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 February 2006 (02.02.2006)

PCT

(10) International Publication Number
WO 2006/010266 A1

(51) International Patent Classification: **C12Q 1/68**

(21) International Application Number:
PCT/CA2005/001180

(22) International Filing Date: 29 July 2005 (29.07.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/592,124 30 July 2004 (30.07.2004) US

(71) Applicant (for all designated States except US): **TM BIO-SCIENCE CORPORATION** [CA/CA]; Suite 900, 439 University Avenue, Toronto, Ontario M5G 1Y8 (CA).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **GORDON, James D.** [CA/CA]; Apt. 1707, 1535 Lakeshore Road East, Mississauga, Ontario L5B 3E2 (CA).

(74) Agents: **CHARI, Santosh K.** et al.; Box 25, Commerce Court West, 199 Bay Street, Toronto, Ontario M5L 1A9 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PI, PL, PT, RO, RU, SC, SD, SH, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report
before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2006/010266 A1

(54) Title: METHOD OF DETECTING MUTATIONS IN THE GENE ENCODING CYTOCHROME P450-2C19

(57) Abstract: The present invention describes a method for the simultaneous identification of two or more mutations located in the gene encoding Cytochrome P450-2C19. Multiplex detection is accomplished using multiplexed tagged allele specific primer extension (ASPE) and hybridization of such extended primers to a probe, preferably an addressable anti-tagged support.

Method of Detecting Mutations in the Gene Encoding Cytochrome P450-2C19

BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

The present invention relates to methods and kits for the detection of mutations
5 located in the gene encoding Cytochrome P450-2C19.

DESCRIPTION OF THE PRIOR ART

Any discussion of the prior art throughout the specification should in no way be
considered as an admission that such prior art is widely known or forms part of common
general knowledge in the field.

10 P450-2C19 is a metabolic enzyme involved in the metabolism of a variety of
clinically important drugs. Drugs metabolized by P450-2C19 include antidepressants,
anxiolytics, antimalarials, and proton pump inhibitors. As with other members of the
P450 family, individuals can be classed as extensive metabolizers or poor metabolizers
based on the level of 2C19 enzyme activity.

15 The poor metabolizer phenotype for P450-2C19 is inherited as an autosomal
recessive trait. Individuals identified as poor metabolizers using *in vivo* or *in vitro*
enzyme activity assays have two defective alleles. Presumably heterozygous individuals
would have an intermediate level of enzyme activity but this is not resolvable
phenotypically using available methods due to the wide inter-individual range in enzyme
20 activity.

Poor metabolizers of P450-2C19 constitute 13 to 23% of Asian populations and
2 to 5% of Caucasians (Desta *et al.*, 2002). The frequency of poor metabolizers has
been less extensively studied in African or African American populations but is thought
to be roughly 4%. The frequency of poor metabolizers can be as high as 38 to 79% in
25 some islands in Polynesia or Micronesia (Kaneko *et al.*, 1999).

The Gene

The CYP2C19 gene is located on chromosome 10q23 in a cluster of CYP genes
including CYP2C8, CYP2C9 and CYP2C18 as well as a number of more distantly
related CYP family members. The gene consists of 9 exons spanning a region of
30 roughly 50 Kbp.

Seven of the most common variants in the gene encoding CYP2C19 are listed
in Table 1.

Table 1 Common Mutations in the Gene Encoding P450-2C19

Variant	Allele	Defect	Activity	Reference
1A>G	P450-2C19*4	Loss of initiation codon	None	Ferguson et al, 1998
358T>C	P450-2C19*8	W120R	None	Ibeanu et al, 1999
395G>A	P450-2C19*6	R132Q; I331V	None	Ibeanu et al, 1998b
636G>A	P450-2C19*3	New stop codon	None	de Morais et al, 1994b
681G>A	P450-2C19*2 (A,B)	splicing defect (new)	None	de Morais et al, 1994a
IVS5+2 T>A	P450-2C19*7	splicing defect	None	Ibeanu et al, 1999
1297C>T	P450-2C19*5 (A,B)	R433W	None/reduced	Xiao et al, 1997 Ibeanu et al, 1998a

[0008] P450-2C19 alleles consist of 1 or more nucleotide variants. In each case the haplotypes can be represented by one variant which is unique to that allele and is responsible for the observed phenotype.

[0009] Multiplex Allele Specific Primer Extension and Solid Support Detection of Mutations

[0010] Multiplex allele specific primer extension, and hybridization of extended primers to a solid support is described generally in the prior art. ASPE technology has been generally described in U.S. Patent No. 4,851,331. The technology is designed to identify the presence or absence of specific polymorphic sites in the genome.

[0011] Multiplex ASPE in conjunction with hybridization to a support for mutation detection can be described generally as follows:

[0012] 1) Amplifying regions of DNA comprising polymorphic loci utilizing a multiplexed, PCR.

[0013] 2) Allele specific extension of primers wherein the amplified regions of DNA serve as target sequences for the allele specific extension. Extension primers that possess a 3' terminal nucleotide which form a perfect match with the target sequence are extended to form extension products. Modified nucleotides are incorporated into the extension product, such nucleotides effectively labelling the extension products for detection purposes. Alternatively, an extension primer may instead comprise a 3' terminal nucleotide which forms a mismatch with the target sequence. In this instance, primer extension does not occur.

3) Hybridizing the extension product to a probe on a solid support, such as a microarray, wherein the probe is complementary to the 5' end of the extension product.

The extension primers used in a methodology as described above, possess unique sequence tags at their 5' ends. For example, the sequence tags may allow the
5 extension products to be captured on a solid support.

Variations of the above technology have been described, for example, in U.S. Patent No. 6,287,778 and PCT Application (WO 00/47766).

It is an object of the present invention to provide a cost effective, rapid, and accurate method for the detection of variants in the gene encoding P450-2C19.

10 SUMMARY OF THE INVENTION

According to a first aspect, the invention provides a method for detecting in a sample the presence or absence of nucleotide variants at polymorphic sites in the gene encoding cytochrome P450-2C19, the method comprising the steps of:

a) amplifying from the sample regions of DNA containing the variants to form
15 amplified DNA products;

b) hybridizing at least two tagged allele specific extension primers to a complementary target sequence in the amplified DNA products, wherein each tagged allele specific extension primer has a 3'-end hybridizing portion capable of hybridizing to the complementary amplified DNA, and wherein the 3' end hybridizing portion of the
20 at least two tagged allele specific extension primers each comprise a sequence selected from the group consisting of bases from position 25 to the 3' terminal nucleotide of SEQ ID NO: 12 to SEQ ID NO: 25, and a 5'-end tag portion complementary to a corresponding anti-tag sequence, the terminal nucleotide of the 3' end hybridizing portion being either complementary to a suspected variant nucleotide or to the
25 corresponding wild type nucleotide of the site;

c) extending the at least two tagged allele specific extension primers, using labelled nucleotides, if the terminal nucleotide of each 3' end hybridizing portion is a perfect match to the complementary amplified DNA products;

d) hybridizing the at least two tagged allele specific extension primers to their
30 corresponding anti-tag sequences and detecting the presence of labelled extension products.

According to a second aspect, the invention provides a method for detecting in a sample the presence or absence of nucleotide variants at polymorphic sites in the gene encoding cytochrome P450-2C19, the method comprising the steps of:

- a) amplifying from the sample regions of DNA containing the selected variants
5 to form amplified DNA products;
- b) hybridizing at least two tagged allele specific extension primers to a complementary target sequence in the amplified DNA products, wherein the at least two tagged allele-specific extension primers are selected from the group consisting of SEQ ID NO: 12 to SEQ ID NO: 25, each tagged allele specific extension primer having a 3'-
10 end hybridizing portion capable of hybridizing to the complementary amplified DNA, and a 5'-end tag portion complementary to a corresponding anti-tag sequence, the terminal nucleotide of the 3' end hybridizing portion being either complementary to a suspected variant nucleotide or to the corresponding wild type nucleotide of the site;
- c) extending the at least two tagged allele specific extension primers, using
15 labelled nucleotides, if the terminal nucleotide of each 3' end hybridizing portion is a perfect match to the complementary amplified DNA product;
- d) hybridizing the at least two tagged allele specific extension primers to their corresponding anti-tag sequences and detecting the presence of labelled extension products.

20 According to a third aspect the invention provides a kit for detecting in a sample the presence or absence of nucleotide variants at polymorphic sites in the gene encoding cytochrome P450-2C19, said kit comprising a set of at least two tagged allele specific extension primers wherein each tagged allele specific extension primer has a 3'-end hybridizing portion including a 3' terminal nucleotide being either complementary to a
25 variant nucleotide or to the corresponding wild type nucleotide of one of the polymorphic sites and a 5'-end tag portion complementary to a corresponding anti-tag sequence, and wherein the at least two tagged allele-specific extension primers are selected from the group consisting of SEQ ID NO: 12 to SEQ ID NO: 25.

Unless the context clearly requires otherwise, throughout the description
30 and the claims, the words "comprise", "comprising", and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of "including, but not limited to".


In one embodiment, the present invention provides a method for detecting the presence or absence of variants in a sample selected from the group of mutations identified in Table 1, the method comprising the steps of:

Amplifying regions of DNA which may contain the above mentioned mutations
5 using at least two PCR primer pairs selected from the group of PCR primer pairs consisting of SEQ ID NO.: 2 and SEQ ID NO: 3, SEQ ID NO.: 4 and SEQ ID NO: 5, SEQ ID NO.: 6 and SEQ ID NO: 7, SEQ ID NO.: 8 and SEQ ID NO: 9 and SEQ ID NO.: 10 and SEQ ID NO: 11.

Hybridizing tagged allele specific extension primers, the allele specific
10 extension primers selected from the group consisting of SEQ ID NO: 12 to SEQ ID NO: 25, to a complementary region of amplified DNA, each tagged allele specific primer having a 3' portion complementary to a region of the amplified DNA, a 3' terminal nucleotide complementary to one allele of one of the variant sites (wild type or mutant) mentioned above, and a 5' portion complementary to a probe (anti-tag) sequence.

15 Extending tagged ASPE primers, whereby a labelled extension product of the primer is synthesised when the 3' terminal nucleotide of the primer is complementary to a corresponding nucleotide in the target sequence; no extension product is synthesised when the terminal nucleotide of the primer is not complementary to the corresponding nucleotide in the target sequence.

20 Hybridizing extension products to a probe and detection of labelled extension products. Detection of a labelled extension product is indicative of the presence of the allele complementary to the 3'-terminal nucleotide of the ASPE primer. In the absence of a labelled extension product, it is determined that the allele corresponding to the 3' end of the ASPE primer is not present in the sample.



1 [0023] In another embodiment, the present invention provides a kit for use in detecting
2 the presence or absence of at least two variants of the gene encoding P450-2C19 identified in
3 Table 1. The kit comprises at least two tagged allele specific extension primers selected from
4 the group consisting of SEQ ID NO: 10 to SEQ ID NO: 19, and two pcr primer pairs selected
5 from the group consisting of SEQ ID NO.: 2 and SEQ ID NO: 3, SEQ ID NO.: 4 and SEQ ID
6 NO: 5, SEQ ID NO.: 6 and SEQ ID NO: 7, and SEQ ID NO.: 8 and SEQ ID NO: 9, and SEQ
7 ID NO.: 10 and SEQ ID NO: 11.

8 BRIEF DESCRIPTION OF THE DRAWINGS

9 [0024] These and other features of the preferred embodiments of the invention will
10 become more apparent in the following detailed description in which reference is made to the
11 appended drawings wherein:

12 [0025] Figure 1 depicts a reaction scheme according to one aspect of the method of the
13 present invention.

14 [0026] Figure 2 depicts the genotyping of an individual having a P450-2C19*2
15 heterozygous genotype.

16 [0027] Figure 3 depicts the genotyping of an individual having a 2C19*8 heterozygous
17 genotype.

18 [0028] Figure 4 depicts the genotyping of an individual having a 2C19*2/*3 compound
19 heterozygous genotype.

20 DESCRIPTION OF THE PREFERRED EMBODIMENTS

21 [0029] The following terms used in the present application will be understood to have the
22 meanings defined below.

23 [0030] The terms "oligonucleotide" and "polynucleotide" as used in the present
24 application refer to DNA sequences being of greater than one nucleotide in length. Such
25 sequences may exist in either single or double-stranded form. Examples of oligonucleotides
26 described herein include PCR primers, ASPE primers, and anti-tags.

27 [0031] The term "allele" is used herein to refer to different versions of a nucleotide
28 sequence.

29 [0032] The expression "allele specific primer extension (ASPE)", as used herein, refers to
30 a mutation detection method utilizing primers which hybridize to a corresponding DNA
31 sequence and which are extended depending on the successful hybridization of the 3'
32 terminal nucleotide of such primer. Amplified regions of DNA serve as target sequences for
33 ASPE primers. Extension primers that possess a 3' terminal nucleotide which form a perfect
34 match with the target sequence are extended to form extension products. Modified

1 nucleotides can be incorporated into the extension product, such nucleotides effectively
2 labelling the extension products for detection purposes. Alternatively, an extension primer
3 may instead comprise a 3' terminal nucleotide which forms a mismatch with the target
4 sequence. In this instance, primer extension does not occur unless the polymerase used for
5 extension inadvertently possesses exonuclease activity.

6 [0033] The term "genotype" refers to the genetic constitution of an organism. More
7 specifically, the term refers to the identity of alleles present in an individual. "Genotyping"
8 of an individual or a DNA sample refers to identifying the nature, in terms of nucleotide base,
9 of the two alleles possessed by an individual at a known polymorphic site.

10 [0034] The term "polymorphism", as used herein, refers to the coexistence of more than
11 one form of a gene or portion thereof.

12 [0035] The term "PCR", as used herein, refers to the polymerase chain reaction. PCR is a
13 method of amplifying a DNA base sequence using a heat stable polymerase and a pair of
14 primers, one primer complementary to the (+)-strand at one end of the sequence to be
15 amplified and the other primer complementary to the (-) strand at the other end of the
16 sequence to be amplified. Newly synthesized DNA strands can subsequently serve as
17 templates for the same primer sequences and successive rounds of heat denaturation, primer
18 annealing and strand elongation results in rapid and highly specific amplification of the
19 desired sequence. PCR can be used to detect the existence of a defined sequence in a DNA
20 sample.

21 [0036] The term "primer", as used herein, refers to a short single-stranded
22 oligonucleotide capable of hybridizing to a complementary sequence in a DNA sample. A
23 primer serves as an initiation point for template dependent DNA synthesis.
24 Deoxyribonucleotides can be joined to a primer by a DNA polymerase. A "primer pair" or
25 "primer set" refers to a set of primers including a 5' upstream primer that hybridizes with the
26 complement of the 5' end of the DNA sequence to be amplified and a 3' downstream primer
27 that hybridizes with the 3' end of the DNA sequence to be amplified. The term "PCR primer"
28 as used herein refers to a primer used for a PCR reaction. The term "ASPE primer" as used
29 herein refers to a primer used for an ASPE reaction.

30 [0037] The term "tag" as used herein refers to an oligonucleotide sequence that is
31 coupled to an ASPE primer. The sequence is generally unique and non-complementary to the
32 human genome while being substantially complementary to a probe sequence. The probe
33 sequence may be, for example, attached to a solid support. Tags serve to bind the ASPE
34 primers to a probe.

- 1 [0038] The term "tagged ASPE primer" as used herein refers to an ASPE primer that is
2 coupled to a tag.
- 3 [0039] The term "anti-tag" or "probe" as used herein refers to an oligonucleotide
4 sequence having a sequence complementary to, and capable of hybridizing to, the tag
5 sequence of an ASPE primer. The "anti-tag" may be coupled to a support.
- 6 [0040] The term "wild type" or "wt" as used herein refers to the normal, or non-mutated,
7 or functional form of a gene.
- 8 [0041] The term "homozygous wild-type" as used herein refers to an individual
9 possessing two copies of the same allele, such allele characterized as being the normal and
10 functional form of a gene.
- 11 [0042] The term "heterozygous" or "HET" as used herein refers to an individual
12 possessing two different alleles of the same gene.
- 13 [0043] The term "homozygous mutant" as used herein refers to an individual possessing
14 two copies of the same allele, such allele characterized as the mutant form of a gene.
- 15 [0044] The term "mutant" as used herein refers to a mutated, or potentially non-
16 functional form of a gene.
- 17 [0045] The present invention was developed in response to a need for a rapid, highly
18 specific, and cost-effective method to genotype individuals susceptible to adverse drug
19 reactions. More specifically, the present invention provides a method for identifying
20 individuals who may have drug metabolism defects resulting from mutations in the P450-
21 2C19 gene.
- 22 [0046] The present invention provides a novel, multiplex method of detecting multiple
23 mutations located in the gene encoding CYP2C19. Specifically, the methodology can be
24 used for the detection of the presence or absence of mutations selected from the group
25 consisting of the variants identified in Table 1. In a preferred embodiment, the present
26 invention provides a method of detecting the presence or absence of all the variants identified
27 in Table 1.
- 28 [0047] The positive detection of one or more of the variants identified in Table 1 may be
29 indicative of an individual having a predisposition to compromised enzyme activity.
- 30 [0048] The present invention is further characterized by a high level of specificity. Such
31 specificity is required in order to ensure that any result generated is a true representation of
32 the genomic target and not simply the result of non-specific interactions occurring between
33 reagents present in reactions. This is especially important for multiplexed DNA-based tests
34 where the numerous sequences present in the reaction mixture, most of which are non-

1 complementary, may interact non-specifically depending on the reaction conditions. The
2 ASPE primer and PCR primer sequences described below have been selected due to their
3 minimal cross-reactivity.

4 [0049] The present invention is also characterized by its high level of accuracy when
5 compared to existing methodologies for the detection of mutations in the gene encoding
6 CYP2C19.

7 [0050] The methodology of the present invention utilizes the combination of multiplex
8 ASPE technology with hybridization of tagged and labelled extension products to probes in
9 order to facilitate detection. Such methodology is suitable for high-throughput clinical
10 genotyping applications.

11 [0051] In one embodiment, the present invention provides a method for detecting the
12 presence or absence of variants in a sample selected from the group of mutations identified in
13 Table 1, the method comprising the steps of:

14 [0052] Amplifying regions of DNA which may contain the above mentioned variants.

15 [0053] Hybridizing at least two tagged allele specific extension primers to a
16 complementary region of amplified DNA, each tagged allele specific primer having a 3'
17 portion complementary to a region of the amplified DNA, a 3' terminal nucleotide
18 complementary to one allele of one of the mutation sites (wild type or mutant) mentioned
19 above, and a 5' portion complementary to a probe sequence.

20 [0054] Extending tagged ASPE primers, whereby a labelled extension product of the
21 primer is synthesised when the 3' terminal nucleotide of the primer is complementary to a
22 corresponding nucleotide in the target sequence; no extension product is synthesised when
23 the terminal nucleotide of the primer is not complementary to the corresponding nucleotide in
24 the target sequence.

25 [0055] Hybridizing extension products to a probe and detection of labelled extension
26 products. Detection of a labelled extension product is indicative of the presence of the allele
27 complementary to the 3'-terminal nucleotide of the ASPE primer. In the absence of a
28 labelled extension product, it is determined that the allele corresponding to the 3' end of the
29 ASPE primer is not present in the sample.

30 [0056] A general overview of the above-mentioned method is presented in figure 1. A
31 DNA sample is first prepared 10 using methods known in the art. Multiplex PCR
32 amplification 20 is conducted in order to amplify regions of DNA containing variant sites in the
33 gene encoding cytochrome P450-2D6. A multiplex ASPE reaction 30 is then conducted. By
34 example only, 33 illustrates a wild type and a mutant allele of a gene. At step 36 ASPE

1 primers are hybridized to amplified regions of DNA. If the 3' terminal nucleotide of an ASPE
 2 primer is complementary to a corresponding nucleotide in the target sequence, a labelled
 3 extension product is formed 39 as will be described further below. The ASPE may be sorted
 4 on an addressable universal sorting array 40 wherein the presence of a labelled extension
 5 product may be detected using, for example, xMAP detection 50.

6 **DNA Sample Preparation**

7 [0057] Patient samples can be extracted with a variety of methods known in the art to
 8 provide nucleic acid (most preferably genomic DNA) for use in the following method. In a
 9 preferred embodiment, a DNA sample is extracted from whole blood.

10 **Amplification**

11 [0058] In a first step at least two regions of DNA from the gene encoding CYP2C19
 12 containing variant sites are amplified.

13 [0059] In a preferred embodiment of the present invention, PCR amplification of regions
 14 containing variant sites in the gene encoding CYP2C19 is initiated using at least two pairs of
 15 PCR primers selected from the group of primer pairs consisting of: SEQ ID NO.: 2 and SEQ
 16 ID NO.: 3, SEQ ID NO.: 4 and SEQ ID NO.: 5, SEQ ID NO.: 6 and SEQ ID NO.: 7, SEQ ID
 17 NO.: 8 and SEQ ID NO.: 9 and SEQ ID NO.: 10 and SEQ ID NO.: 11.

18 [0060] The relationships of each pair of primers to the mutation sites listed in Table 1 is
 19 presented in Table 2.

20 **Table 2: Primer Pairs Used to Amplify Regions Containing CYP2C19 Mutations**

PCR Primer Pair	Variants present in Amplimer
SEQ ID NO: 2 and 3	CYP2C19*4
SEQ ID NO: 4 and 5	CYP2C19*6 and CYP2C19*8
SEQ ID NO: 6 and 7	CYP2C19*3
SEQ ID NO: 8 and 9	CYP2C19*2 and CYP2C19*7
SEQ ID NO: 10 and 11	CYP2C19*5

21 [0061] An individual skilled in the art will recognize that alternate PCR primers could be
 22 used to amplify the target polymorphic regions, and deletion and duplication regions,
 23 however, in a preferred embodiment the primers listed in Table 2 are selected due to their
 24 minimal non-specific interaction with other sequences in the reaction mixture.

25 **ASPE**

1 [0062] The ASPE step of the method of the present invention is conducted using tagged
2 ASPE primers selected from the group of ASPE primers consisting of SEQ ID NO: 12 to
3 SEQ ID NO.: 25.

4 [0063] The ASPE primer set of the present invention has been optimized to ensure high
5 specificity and accuracy of diagnostic tests utilizing such allele specific primers.

6 [0064] Table 3 presents a listing of the ASPE primers used in a preferred embodiment of
7 the present invention. The suffix "wt" indicates an ASPE primer used to detect the wild type
8 form of the gene encoding CYP2C19 at a specific variant site. The suffix "mut" indicates an
9 ASPE primer used to detect a mutant form of the gene encoding CYP2C19 at a specific
10 variant site. Bases 1 to 24 of each of SEQ ID NO.: 12 to SEQ ID NO: 25 are the 5' portions
11 of the ASPE primers that are complementary to specific probe sequences. Although the
12 specific sequences listed in Table 2 are preferred, in alternate embodiments of the present
13 invention, it is possible to combine different 5' portions of the sequences in Table 3 (bases 1
14 to 24 of SEQ ID NOs: 12 to 25) with different 3' end hybridizing portions of the sequences in
15 Table 2 (bases 25 and up of SEQ ID NOs: 12 to 25).

16 [0065] The ASPE primers of the present invention are listed in Table 3.

17 **Table 3: P450-2C19 ASPE Primer Sequences**

SEQ ID NO:	Allele Detected	Direction
12	2C19*2WT	Reverse
13	2C19*2Mut	Reverse
14	2C19*3WT	Forward
15	2C19*3Mut	Forward
16	2C19*4WT	Reverse
17	2C19*4Mut	Reverse
18	2C19*5WT	Reverse
19	2C19*5Mut	Reverse
20	2C19*6WT	Reverse
21	2C19*6mut	Reverse
22	2C19*7WT	Forward
23	2C19*7Mut	Forward
24	2C19*8WT	Reverse
25	2C19*8Mut	Reverse

18 [0066] The 3' end hybridizing portion of the extension primer is hybridized to the
19 amplified material. Where the 3' terminal nucleotide of an ASPE primer is complementary to
20 the polymorphic site, primer extension is carried out using a modified nucleotide. Where the
21 3' terminal nucleotide of the ASPE primer is not complementary to the polymorphic region,
22 no primer extension occurs.

1 [0067] In one embodiment, labelling of the extension products is accomplished through
2 the incorporation of biotinylated nucleotides into the extension product which may be
3 identified using fluorescent (Streptavidin-Phycoerythrin) or chemiluminescent (Streptavidin-
4 Horseradish Peroxidase) reactions. However, an individual skilled in the art will recognize
5 that other labelling techniques may be utilized. Examples of labels useful for detection
6 include but are not limited to radiolabels, fluorescent labels (e.g fluorescein and rhodamine),
7 nuclear magnetic resonance active labels, positron emitting isotopes detectable by a positron
8 emission tomography ("PET") scanner, and chemiluminescers such as luciferin, and
9 enzymatic markers such as peroxidase or phosphatase.

10 [0068] Each ASPE primer used in the methodology as described above, possess a unique
11 sequence tag at their 5' ends. The sequence tags allow extension products to be detected with
12 a high degree of specificity, for example, through capture on a solid support in order to
13 facilitate detection.

14 [0069] **Detection**

15 [0070] The tagged 5' portions of the allele specific primers of the present invention are
16 complementary to probe sequences. Upon hybridization of the allele specific primers to a
17 corresponding probe sequence the presence of extension products can be detected.

18 [0071] In a preferred embodiment, probes used in the methodology of the present
19 invention are coupled to a solid support, for example a 'universal' bead-based microarray.

20 [0072] Examples of supports that can be used in the present invention include, but are not
21 limited to, bead based microarrays and 2D glass microarrays. The preparation, use, and
22 analysis of microarrays are well known to persons skilled in the art. (See, for example,
23 Brennan, T. M. et al. (1995) U.S. Pat. No. 5,474,796; Schena, et al. (1996) Proc. Natl. Acad.
24 Sci. 93:10614-10619; Baldeschweiler et al. (1995), PCT Application WO95/251116; Shalon,
25 D. et al. (1995) PCT application WO95/35505; Heller, R. A. et al. (1997) Proc. Natl. Acad.
26 Sci. 94:2150-2155; and Heller, M. J. et al. (1997) U.S. Pat. No. 5,605,662.). Detection can be
27 achieved through arrays using, for example, chemiluminescence or fluorescence technology
28 for identifying the presence or absence of specific mutations.

29 [0073] Universal arrays function as sorting tools indirectly detecting the target of interest
30 and are designed to be isothermal and minimally cross-hybridizing as a set. Examples of
31 microarrays which can be used in the present invention include, but should not be limited to,
32 Luminex's[®] bead based microarray systems, and Metragenix's[™] Flow Thru chip technology.

33 [0074] In one embodiment, for example, Luminex's 100 xMAP[™] fluorescence based
34 solid support microarray system is utilized. Anti-tag sequences complementary to the tag

1 regions of the ASPE primers/extension products, described above, are coupled to the surface
2 of internally fluorochrome-color-coded microspheres. An array of anti-tag microspheres is
3 produced, each set of microspheres having its own characteristic spectral address. The
4 mixture of tagged, extended, biotinylated ASPE primers is combined with the array of anti
5 tagged microspheres and is allowed to hybridize under stringent conditions.

6 [0075] In a reaction mixture, a fluorescent reporter molecule (e.g. streptavidin-
7 phycoerythrin) is used to detect labelled extension products which are synthesized when the
8 terminal nucleotide of an ASPE primer is complementary to a corresponding nucleotide in
9 the target sequence.

10 [0076] The reaction mixture, comprising microspheres, extension products etc. is injected
11 into a reading instrument, for example Luminex's 100 xMAP™, which uses microfluidics to
12 align the microspheres in single file. Lasers are used to illuminate the colors both internal to
13 the microspheres, and attached to the surface in the form of extension products hybridized to
14 anti-tag sequences. The Luminex 100 xMAP™, interprets the signal received and identifies
15 the presence of wild type and/or mutant alleles. The presence of the mutant allele of any one
16 or more of the mutations presented in Table 1 may be indicative a predisposition for adverse
17 drug reactions. Software can be provided which is designed to analyze data associated with
18 the specific extension products and anti-tagged microspheres of the present invention.

19 [0077] In another embodiment, the Metragenix Flow-Thru three dimensional
20 microchannel biochip (Cheek, B.J., Steel A.B., Torres, M.P., Yu, Y., and Yang H. Anal.
21 Chem. 2001, 73, 5777-5783) is utilized for genotyping as known in the art. In this
22 embodiment, each set of microchannels represents a different universal anti-tag population.
23 Anti-tag sequences corresponding to the tag regions of the ASPE primers/extension products,
24 described above, are attached to the inner surface of multiple microchannels comprising a
25 cell. Multiple cells make up a chip. The reaction mixture, including biotinylated extension
26 products flows through the cells in the presence of a chemiluminescent reporter substrate
27 such as streptavidin-horseradish peroxidase. Microarray chips can be imaged using
28 technology known in the art, such as an ORCA-ER CCD (Hamamatsu Photonics K. K.,
29 Hamamatsu City, Japan), and imaging software, in order to identify the genotype of an
30 individual.

31 Kits

32 [0078] In an additional embodiment, the present invention provides kits for the multiplex
33 detection of mutations in the gene encoding CYP2C19.

1 [0079] A kit that can be used for detection of the mutations of interest may contain the
2 following components including: a PCR primer mix for amplifying regions containing
3 mutation sites of interest (optionally including dNTPs), an ASPE primer mix for generation
4 of labelled extension products (optionally including dNTPs) and a solid support, such as
5 microarray beads, the beads having anti-tags complementary to the tagged regions of the
6 ASPE primers. In addition, an individual skilled in the art would recognize other components
7 which could be included in such kits including, for example, buffers and polymerases.

8 [0080] Kits of the present invention may include PCR primer pairs, ASPE primers, and
9 tagged supports for all the mutations to be detected, or may be customized to best suit the
10 needs of an individual end user. For example, if an end user wishes to determine the
11 presence or absence of only four of the mutations in the CYP2C19 gene, a kit can be
12 customized to include only the PCR primer pairs, ASPE primers, and support required for the
13 detection of the desired mutations. As such, the end user of the product can design a kit to
14 match their specific requirements. In addition, the end user can also control the tests to be
15 conducted at the software level when using, for example, a universal bead based-microarray
16 for detection. For example, software can be provided with a kit, such software reading only
17 the beads for the desired mutations or reporting only the results from the desired mutation
18 data. Similar control of data reporting by software can be obtained when the assay is
19 performed on alternate platforms.

20 [0081] An individual skilled in the art will recognize that although the present method
21 has been described in relation to the specific mutations identified in Table 1, PCR primers
22 and ASPE primers used to detect additional mutations could be included in the above method
23 and kits.

24 [0082] **EXAMPLE #1: ASPE/Microarray Detection of Mutations in the Gene**
25 **Encoding CYP2C19**

26 [0083] **1) Oligonucleotides**

27 [0084] All oligonucleotides were synthesized by Integrated DNA Technologies
28 (Coralville, IA). PCR primers were unmodified and were purified by standard desalting
29 procedures. Universal anti-tags (probes) were 3'-C₇ amino-modified for coupling to
30 carboxylated microspheres. All anti-tags were reverse phase HPLC-purified. Chimeric
31 ASPE primers which consisted of a 24mer universal tag sequence 5' to the allele-specific
32 sequence were also unmodified but were purified by polyacrylamide gel electrophoresis.
33 Following reconstitution, exact oligonucleotide concentrations were determined
34 spectrophotometrically using extinction coefficients provided by the supplier. Reconstituted

1 oligonucleotides were scanned between 200 and 800 nm and absorbance was measured at
2 260 nm to calculate oligonucleotide concentration.

3 **[0085] 2) Reagents**

4 **[0086]** Platinum Taq, Platinum Tsp, individual dNTPs and biotin-dCTP were purchased
5 from Invitrogen Corporation (Carlsbad, CA). Shrimp alkaline phosphatase and exonuclease I
6 were purchased from USB Corporation (Cleveland, OH). Carboxylated fluorescent
7 microspheres were provided by Luminex Corporation (Austin, TX). The EDC cross-linker
8 (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride) was purchased from Pierce
9 (Rockford, IL). OmniPur reagents including MES (2-(N-morpholino)ethane sulfonic acid),
10 10% SDS, NaCl, Tris, Triton X-100, Tween-20 and TE buffer were purchased from EM
11 Science (Darmstadt, Germany). The streptavidin-conjugated phycoerythrin was obtained
12 from Molecular Probes Inc. (Eugene, OR).

13 **[0087] 3) Genotyping**

14 **[0088]** a) MULTIPLEX PCR (5-plex): Multiplex PCR was carried out using 25 ng
15 genomic DNA in a 25 uL final volume. A 'no target' PCR negative control was included
16 with each assay run. The reaction consisted of 20 mmol/L Tris-HCl, pH 8.4, 50 mmol/L
17 KCl, 2.5 mmol/L MgCl₂, 200 umol/L each dNTP, 5 units Platinum Taq and primers at 150
18 nmol/L. Samples were cycled in an MJ Research PTC-200 thermocycler (Waterdown, MA)
19 with cycling parameters set at 95°C for 5 minutes followed by 30 cycles at 95°C for 30
20 seconds, 58°C for 30 seconds and 72°C for 30 seconds. Samples were then held at 72°C for
21 5 minutes and kept at 4°C until use.

22 **[0089]** b) ALLELE-SPECIFIC PRIMER EXTENSION: Prior to the ASPE reaction, each
23 PCR reaction was treated with shrimp alkaline phosphatase (SAP) to inactivate any
24 remaining nucleotides (particularly dCTP) so that biotin-dCTP could be efficiently
25 incorporated during the primer extension reaction. Each PCR reaction was also treated with
26 exonuclease I (EXO) to degrade remaining PCR primers in order to avoid any interference
27 with the tagged ASPE primers and the extension reaction itself. To each 25 uL PCR reaction,
28 2.0 uL SAP (2.0 units) and 0.5 uL EXO (5 units) were added directly and the sample was
29 vortexed and briefly centrifuged. Samples were then incubated at 37°C for 30 minutes
30 followed by a 15 minute incubation at 99°C to inactivate the enzymes. Samples were then
31 added directly to the ASPE reaction.

32 **[0090]** Multiplex ASPE was carried out using 5 uL of treated PCR product in a final
33 volume of 20 uL. Each reaction consisted of 20 mmol/L Tris-HCl pH 8.4, 50 mmol/L KCl,
34 1.25 mmol/L MgCl₂, 5 umol/L biotin-dCTP, 5 umol/L each of dATP, dGTP and dTTP, 1.5

1 units Platinum Tsp and 25 nmol/L ASPE primer pool. The ASPE reactions were incubated at
2 96°C for 2 minutes and then subjected to 40 cycles at 94°C for 30 seconds, 52°C for 30
3 seconds and 74°C for 60 seconds. Reactions were then held at 4°C until use.

4 [0091] c) BEAD COUPLING: Amino-modified anti-tag sequences were coupled to
5 carboxylated microspheres following Luminex's one-step carbodiimide coupling procedure.
6 Briefly, 5×10^6 microspheres were combined with 1 nmol NH_2 -oligo in a final volume of 50
7 μL 0.1 mol/L MES, pH 4.5. A 10 mg/mL EDC working solution was prepared just prior to
8 use and 2.5 μL was added to the bead mixture and incubated for 30 minutes. A second 2.5 μL
9 aliquot of freshly prepared EDC was added followed by an additional 30 minute incubation.
10 Following washes in 0.02% (v/v) Tween-20 and 0.1% (w/v) SDS, the anti-tag coupled beads
11 were resuspended in 100 μL TE buffer (10 mmol/L Tris, pH 8.0, 1 mmol/L EDTA). Bead
12 concentrations were determined using a Beckman Coulter Z2 Particle Count and Size
13 Analyzer (Coulter Corp, Miami FL).

14 [0092] d) UNIVERSAL ARRAY HYBRIDIZATION: Each hybridization reaction was
15 carried out using approximately 2500 beads of each of the 10 anti-tag bearing bead
16 populations. The beads were combined in hybridization buffer (0.22 mol/L NaCl, 0.11 mol/L
17 Tris, pH 8.0 and 0.088% (v/v) Triton X-100) and 45 μL of the mix were added to each well of
18 an MJ Research 96-well plate (Reno, NV). A 5 μL aliquot of each ASPE reaction was then
19 added directly to each well. The samples were then heated to 96°C for 2 minutes in an MJ
20 Research PTC-100 followed by a one hour incubation at 37°C. Following this incubation,
21 samples were filtered through a 1.2 μm Durapore Membrane (Millipore Corp, Bedford, MA)
22 and washed once using wash buffer (0.2 mol/L NaCl, 0.1 mol/L Tris, pH 8.0 and 0.08% (v/v)
23 Triton X-100). The beads were then resuspended in 150 μL reporter solution (1 $\mu\text{g}/\text{mL}$
24 streptavidin-conjugated phycoerythrin in wash buffer) and incubated for 15 minutes at room
25 temperature. The reactions were read on the Luminex xMAP. Acquisition parameters were
26 set to measure 100 events per bead population and a 100 μL sample volume. A gate setting
27 was established prior to running the samples and maintained throughout the course of the
28 study.

29 [0093] Figures 2 to 4 depict a examples of results obtained for samples from different
30 individuals using the method of the present invention. Figure 2 depicts the genotyping of an
31 individual having a P450-2C19*2 heterozygote genotype. Figure 3 depicts the genotyping of
32 an individual having a 2C19*8 heterozygote genotype. Figure 4 depicts the genotyping of an
33 individual having a 2C19*2/*3 compound heterozygote genotype. Data for wild type and

1 mutant alleles is expressed as an Allelic Ratio (i.e., the net signal for the particular variant
2 over the net signal for all variants at a specific position).

3 **[0094]** All publications, patents and patent applications are herein incorporated by
4 reference in their entirety to the same extent as if each individual publication, patent or patent
5 application was specifically and individually indicated to be incorporated by reference in its
6 entirety.

7 **[0095]** Although the invention has been described with reference to certain specific
8 embodiments, various modifications thereof will be apparent to those skilled in the art
9 without departing from the spirit and scope of the invention as outlined in the claims
10 appended hereto.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:-

1. A method for detecting in a sample the presence or absence of nucleotide variants at polymorphic sites in the gene encoding cytochrome P450-2C19, the method comprising the steps of:
 - 5 a) amplifying from the sample regions of DNA containing the variants to form amplified DNA products;
 - b) hybridizing at least two tagged allele specific extension primers to a complementary target sequence in the amplified DNA products, wherein each tagged allele specific extension primer has a 3'-end hybridizing portion capable of hybridizing
10 to the complementary amplified DNA, and wherein the 3' end hybridizing portion of the at least two tagged allele specific extension primers each comprise a sequence selected from the group consisting of bases from position 25 to the 3' terminal nucleotide of SEQ ID NO: 12 to SEQ ID NO: 25, and a 5'-end tag portion complementary to a corresponding anti-tag sequence, the terminal nucleotide of the 3' end hybridizing
15 portion being either complementary to a suspected variant nucleotide or to the corresponding wild type nucleotide of the site;
 - c) extending the at least two tagged allele specific extension primers, using labelled nucleotides, if the terminal nucleotide of each 3' end hybridizing portion is a perfect match to the complementary amplified DNA products;
 - 20 d) hybridizing the at least two tagged allele specific extension primers to their corresponding anti-tag sequences and detecting the presence of labelled extension products.
2. The method of claim 1 wherein the 5'-end tag portions of the at least two tagged allele specific primers each comprise a sequence selected from the group consisting of
25 bases 1 to 24 of SEQ ID NO: 12 to SEQ ID NO: 25 and wherein the sequence of each 5' end tag portion is unique.
3. The method of claim 1 or claim 2 wherein the anti-tag sequence is coupled to a solid support.
4. The method of claim 3 wherein the solid support is selected from the group
30 consisting of beads, spectrally coded beads, and a chip based microarray.
5. The method of any one of claims 1 to 4 wherein the step of amplifying is conducted by PCR using a set of PCR amplification primers, said set of PCR amplification primers comprising primer pairs selected from the group of pairs

consisting of: SEQ ID NO.: 2 and SEQ ID NO: 3, SEQ ID NO.: 4 and SEQ ID NO: 5, SEQ ID NO.: 6 and SEQ ID NO: 7, SEQ ID NO.: 8 and SEQ ID NO: 9 and SEQ ID NO.: 10 and SEQ ID NO: 11, wherein the PCR primer pairs are selected according to the relationship of each primer pair to the selected variants to be detected.

- 5 6. A method for detecting in a sample the presence or absence of nucleotide variants at polymorphic sites in the gene encoding cytochrome P450-2C19, the method comprising the steps of:
- a) amplifying from the sample regions of DNA containing the selected variants to form amplified DNA products;
 - 10 b) hybridizing at least two tagged allele specific extension primers to a complementary target sequence in the amplified DNA products, wherein the at least two tagged allele-specific extension primers are selected from the group consisting of SEQ ID NO: 12 to SEQ ID NO: 25, each tagged allele specific extension primer having a 3'-end hybridizing portion capable of hybridizing to the complementary amplified DNA,
15 and a 5'-end tag portion complementary to a corresponding anti-tag sequence, the terminal nucleotide of the 3' end hybridizing portion being either complementary to a suspected variant nucleotide or to the corresponding wild type nucleotide of the site;
 - c) extending the at least two tagged allele specific extension primers, using labelled nucleotides, if the terminal nucleotide of each 3' end hybridizing portion is a
20 perfect match to the complementary amplified DNA product;
 - d) hybridizing the at least two tagged allele specific extension primers to their corresponding anti-tag sequences and detecting the presence of labelled extension products.
7. The method of claim 6, comprising hybridizing a tagged allele-specific extension
25 primer of each of SEQ ID NO: 12 to SEQ ID NO: 25 to a complementary target sequence in the amplified DNA products.
8. The method of claim 6 or claim 7 wherein the anti-tag sequence is coupled to a solid support.
9. The method of claim 8 wherein the solid support is selected from the group
30 consisting of beads, spectrally coded beads, and a chip based microarray.

10. The method of any one of claims 6 to 9 wherein the step of amplifying is conducted by PCR using a set of PCR amplification primers, said set of PCR amplification primers comprising primer pairs selected from the group of pairs consisting of:
- 5 SEQ ID NO.: 2 and SEQ ID NO: 3, SEQ ID NO.: 4 and SEQ ID NO: 5, SEQ ID NO.: 6 and SEQ ID NO: 7, SEQ ID NO.: 8 and SEQ ID NO: 9 and SEQ ID NO.: 10 and SEQ ID NO: 11, wherein the PCR primer pairs are selected according to the relationship of each primer pair to the selected variants to be detected.
11. The method of claim 10, wherein the set of PCR amplification primers comprise
- 10 SEQ ID NO.: 2 and SEQ ID NO: 3, SEQ ID NO.: 4 and SEQ ID NO: 5, SEQ ID NO.: 6 and SEQ ID NO: 7, SEQ ID NO.: 8 and SEQ ID NO: 9 and SEQ ID NO.: 10 and SEQ ID NO: 11.
12. A kit for detecting in a sample the presence or absence of nucleotide variants at polymorphic sites in the gene encoding cytochrome P450-2C19, said kit comprising a
- 15 set of at least two tagged allele specific extension primers wherein each tagged allele specific extension primer has a 3'-end hybridizing portion including a 3' terminal nucleotide being either complementary to a variant nucleotide or to the corresponding wild type nucleotide of one of the polymorphic sites and a 5'-end tag portion complementary to a corresponding anti-tag sequence, and wherein the at least two
- 20 tagged allele-specific extension primers are selected from the group consisting of SEQ ID NO: 12 to SEQ ID NO: 25.
13. The kit of claim 12, comprising the tagged allele-specific extension primers of SEQ ID NO: 12 to SEQ ID NO: 25.
14. The kit of claim 12 or claim 13 further comprising a set of PCR amplification
- 25 primers for amplifying regions of DNA containing the polymorphic sites, said set of PCR amplification primers comprising primer pairs selected from the group of pairs consisting of:
- SEQ ID NO.: 2 and SEQ ID NO: 3, SEQ ID NO.: 4 and SEQ ID NO: 5, SEQ ID NO.: 6 and SEQ ID NO: 7, SEQ ID NO.: 8 and SEQ ID NO: 9 and SEQ ID NO.: 10 and SEQ
- 30 ID NO: 11, wherein the PCR primer pairs are selected according to the relationship of each primer pair to the selected variants to be detected.

15. The kit of claim 14, wherein the set of PCR amplification primers comprise SEQ ID NO.: 2 and SEQ ID NO: 3, SEQ ID NO.: 4 and SEQ ID NO: 5, SEQ ID NO.: 6 and SEQ ID NO: 7, SEQ ID NO.: 8 and SEQ ID NO: 9 and SEQ ID NO.: 10 and SEQ ID NO: 11.
- 5 16. The kit of any one of claims 12 to 14 further comprising a set of anti-tags, each anti-tag being complementary to nucleotides 1-24 of the selected at least two tagged allele-specific extension primers.
17. The kit of claim 16 wherein the anti-tags are coupled to a support.
18. A method for detecting in a sample the presence or absence of nucleotide
10 variants at polymorphic sites in the gene encoding cytochrome P450-2C19, substantially as herein described with reference to any one of the embodiments of the invention illustrated in the accompanying drawings and/or examples.
19. A kit for detecting in a sample the presence or absence of nucleotide variants at
15 polymorphic sites in the gene encoding cytochrome P450-2C19, substantially as herein described with reference to any one of the embodiments of the invention illustrated in the accompanying drawings and/or examples.




FIGURE 1

Figure 2




Figure 3





Figure 4



SEQUENCE LISTING

<110> Gordon, Jim
 TM Bioscience Corporation
 <120> Method of Detecting Mutations in the Gene Encoding Cytochrome
 P450-2C19
 <130> 53436/159
 <150> U.S. 60/592,124
 <151> July 30, 2004
 <160> 25
 <170> PatentIn version 3.2
 <210> 1
 <211> 1473
 <212> DNA
 <213> Homo sapiens
 <300>
 <301> Koukouritaki, S.B., Manro, J.R., Marsh, S.A., Stevens, J.C.,
 Rettie, A.E., McCarver, D.G. and Hines, R.N.
 <302> Developmental expression of human hepatic CYP2C9 and CYP2C19
 <303> Journal of Pharmacology and Experimental Therapeutics
 <304> 308
 <305> 3
 <306> 965-974
 <307> 2004-03
 <308> NM_000769
 <309> 2004-07-15
 <313> (1)..(1473)
 <300>
 <308> NM_000769
 <309> 2004-07-15
 <313> (1)..(1473)
 <400> 1
 atggatcctt ttgtggtcct tgtgctctgt ctctcatggt tgcttctcct ttcaatctgg 60
 agacagagct ctgggagagg aaaactccct cctggcccca ctctctccc agtgattgga 120
 aatatacctac agatagatat taaggatgac agcaaatcct taaccaatct ctcaaaaatc 180
 tatggccctg tgttactct gtattttggc ctggaacgca tgggtgtgct gcatggatat 240
 gaagtgtgga aggaagccct gattgatctt ggagaggagt tttctggaag aggccatttc 300
 ccactggctg aaagagctaa cagaggattt ggaatcgttt tcagcaatgg aaagagatgg 360
 aaggagatcc ggcggttctc cctcatgacg ctgcggaatt ttgggatggg gaagaggagc 420
 attgaggacc gtgttcaaga ggaagcccgc tgccttggg aggagttgag aaaaaccaag 480
 gcttcaccct gtgatccac ttctatcctg ggctgtgctc cctgcaatgt gatctgctcc 540
 attattttcc agaaacggtt cgattataaa gatcagcaat ttcttaactt gatggaaaaa 600
 ttgaatgaaa acatcaggat tgtaagcacc ccctggatcc agatatgcaa taattttccc 660
 actatcattg attatttccc ggaacccat aacaaattac ttaaaaacct tgcttttatg 720
 gaaagtgata ttttgagaa agtaaaagaa caccaagaat cgatggacat caacaaccct 780
 cgggacttta ttgattgctt cctgatcaaa atggagaagg aaaagcaaaa ccaacagtct 840

gaattcacta ttgaaaactt ggtaatcact gcagctgact tacttgagc tgggacagag 900
 aacaacagca caaccctgag atatgtctc cttctcctgc tgaagcacc agaggtcaca 960
 gctaaagtcc aggaagagat tgaacgtgc attggcagaa accggagccc ctgcatgcag 1020
 gacaggggcc acatgcccta cacagatgct gtggtgcacg aggtccagag atacatcgac 1080
 ctcatcccca ccagcctgcc ccatgcagtg acctgtgacg ttaaattcag aaactacctc 1140
 attccaagg gcacaacat attaacttcc ctcaactctg tgctacatga caacaagaa 1200
 ttccaacc cagagatggt tgaccctcgt cactttctgg atgaaggagg aaattttaag 1260
 aaaagtaact acttcatgcc tttctcagca ggaaaacgga tttgtgtggg agagggcctg 1320
 gcccgcattg agctgttttt attcctgacc ttcattttac agaactttaa cctgaaatct 1380
 ctgattgacc caaaggacct tgacacaact cctgtgtgca atggatttgc ttctgtcccg 1440
 cccttctatc agctgtgctt cattcctgtc tga 1473

<210> 2
 <211> 28
 <212> DNA
 <213> Artificial

<220>
 <223> Forward Primer

<400> 2
 actttatcca tcaaagaggc acacacac 28

<210> 3
 <211> 32
 <212> DNA
 <213> Artificial

<220>
 <223> Reverse Primer

<400> 3
 gcatacttac attggttaag gatttgctga ca 32

<210> 4
 <211> 26
 <212> DNA
 <213> Artificial

<220>
 <223> Forward Primer

<400> 4
 gatggggagg atggaaaaca gactag 26

<210> 5
 <211> 30
 <212> DNA
 <213> Artificial

<220>
 <223> Reverse Primer

<400> 5
 gtccagaaag gtcagtata gagagtatgt 30

<210> 6
 <211> 36
 <212> DNA
 <213> Artificial
 <220>
 <223> Forward Primer
 <400> 6
 attatttaac cagctaggct gtaattgta attcga 36

<210> 7
 <211> 30
 <212> DNA
 <213> Artificial
 <220>
 <223> Reverse Primer
 <400> 7
 tcaaaaatgt acttcagggc ttgtcaata 30

<210> 8
 <211> 31
 <212> DNA
 <213> Artificial
 <220>
 <223> Forward Primer
 <400> 8
 caaccagagc ttggcatatt gtatctatac c 31

<210> 9
 <211> 36
 <212> DNA
 <213> Artificial
 <220>
 <223> Reverse Primer
 <400> 9
 gttaaacatc cgtagtaaac acaaaactag tcaatg 36

<210> 10
 <211> 32
 <212> DNA
 <213> Artificial
 <220>
 <223> Forward Primer
 <400> 10
 catctatcta ctcatccctc ctatgattca cc 32

<210> 11
 <211> 31
 <212> DNA
 <213> Artificial
 <220>
 <223> Reverse Primer

<400> 11		
ggtcagaaga agcatcacag atagtgaat t		31
<210> 12		
<211> 46		
<212> DNA		
<213> Artificial		
<220>		
<223> ASPE Primer		
<400> 12		
ctttctcata ctttcaacta atttaagtaa tttgttatgg gttccc		46
<210> 13		
<211> 46		
<212> DNA		
<213> Artificial		
<220>		
<223> ASPE Primer		
<400> 13		
aatttcttct ctttcttca caataagtaa tttgttatgg gttcct		46
<210> 14		
<211> 44		
<212> DNA		
<213> Artificial		
<220>		
<223> ASPE Primer		
<400> 14		
taacataact tcttcattat tcacggattg taagcacccc ctgg		44
<210> 15		
<211> 44		
<212> DNA		
<213> Artificial		
<220>		
<223> ASPE Primer		
<400> 15		
acactcattt aacactatth cattggattg taagcacccc ctga		44
<210> 16		
<211> 44		
<212> DNA		
<213> Artificial		
<220>		
<223> ASPE Primer		
<400> 16		
aatatacatc tcaaacattt acacaggacc acaaaaggat ccat		44
<210> 17		
<211> 44		
<212> DNA		
<213> Artificial		

<220>
 <223> ASPE Primer
 <400> 17
 attacaata actactaata ctctaggacc acaaaaggat ccac 44

<210> 18
 <211> 48
 <212> DNA
 <213> Artificial
 <220>
 <223> ASPE Primer
 <400> 18
 tctcaacata taactcattt cttacaggcc ctctcccaca caaatccg 48

<210> 19
 <211> 48
 <212> DNA
 <213> Artificial
 <220>
 <223> ASPE Primer
 <400> 19
 cataatcaat ttcaactttc tactcaggcc ctctcccaca caaatcca 48

<210> 20
 <211> 44
 <212> DNA
 <213> Artificial
 <220>
 <223> ASPE Primer
 <400> 20
 tcttactaat ttcaatactc ttaccttccc catcccaaaa ttcc 44

<210> 21
 <211> 44
 <212> DNA
 <213> Artificial
 <220>
 <223> ASPE Primer
 <400> 21
 acacttatct ttcaattcaa ttaccttccc catcccaaaa ttct 44

<210> 22
 <211> 46
 <212> DNA
 <213> Artificial
 <220>
 <223> ASPE Primer
 <400> 22
 atactaaaca attctcttta ctactcctga tcaaaatgga gaaggt 46

<210> 23

<211> 46
<212> DNA
<213> Artificial

<220>
<223> ASPE Primer

<400> 23
acaatataca tcaacttaaac tttctcctga tcaaaatgga gaagga 46

<210> 24
<211> 44
<212> DNA
<213> Artificial

<220>
<223> ASPE Primer

<400> 24
ctcaattact acatacattt aacaaaacgc cggatctcct tcca 44

<210> 25
<211> 44
<212> DNA
<213> Artificial

<220>
<223> ASPE Primer

<400> 25
ctaactataa ttttcataca cataaaaacgc cggatctcct tccg 44